Free Trial
→ Undiscovered Sub-$1 Gold-Silver Royalty Stock Takes Flight (From Digest Publishing) (Ad)tc pixel
NASDAQ:COCP

Cocrystal Pharma Earnings Date & Estimates

Cocrystal Pharma logo
$1.02 -0.01 (-0.97%)
Closing price 04:00 PM Eastern
Extended Trading
$1.04 +0.02 (+1.96%)
As of 06:33 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cocrystal Pharma is estimated to report earnings on Friday, November 13, 2026.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Announcement Date
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Cocrystal Pharma

Cocrystal Pharma is expected to post earnings of -$0.17 per share on revenue of $0.11 million. In the same quarter a year earlier Cocrystal Pharma reported -$0.19 per share. Cocrystal Pharma last reported on August 13, 2026, posting -$0.23 per share and missing the -$0.17 consensus estimate. Cocrystal Pharma has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.17
Expected Revenue
$0.11 million
Prior-Year EPS
-$0.19

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.23 (Missed by -$0.06)
Last Quarter Revenue
$0.11 million
EPS Beat Rate
5 of last 8 quarters

Prepare for the Earnings Call

Cocrystal Pharma Earnings FAQ

Cocrystal Pharma (NASDAQ:COCP) is estimated to report earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it.

Analysts expect Cocrystal Pharma to post earnings of -$0.17 per share for the quarter.

The consensus revenue estimate for Cocrystal Pharma is $0.11 million for the quarter.

Cocrystal Pharma Earnings Headlines

Brokers Offer Predictions for COCP Q3 Earnings
October 13 at 8:13 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31115279
Brokers Set Expectations for COCP Q4 Earnings
October 12, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31109034
Financial legend: “This is bad, really bad...”
Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel
October 16 at 1:00 AM  |  Weiss Ratings (Ad)
Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment
September 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/09/3358509/0/en/cocrystal-pharma-announces-last-subject-dosed-in-phase-1b-human-challenge-study-evaluating-cdi-988-for-norovirus-prevention-and-treatment.html
COCP: $5 Million Private Placement with OPKO Health
August 20, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/cocp-5-million-private-placement-112000829.html
Cocrystal Pharma strengthens board with antiviral expert appointment
August 19, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/COCP/pressreleases/3916268/cocrystal-pharma-strengthens-board-with-antiviral-expert-appointment/
See More Cocrystal Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cocrystal Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cocrystal Pharma and other key companies, straight to your email.

About Cocrystal Pharma

Cocrystal Pharma (NASDAQ:COCP) is a clinical-stage biotechnology company focused on discovering and developing antiviral therapies. The company uses a structure-based drug discovery platform to identify small-molecule compounds designed to interfere with essential viral replication proteins.

Its research programs have targeted a range of viral diseases, including influenza A, norovirus and coronaviruses. Cocrystal’s development activities have included orally administered antiviral candidates intended for the treatment or prevention of viral infections, with programs advancing through a combination of preclinical research and clinical development.

Founded in 2007 and formerly known as BioZone Pharmaceuticals, the company adopted the Cocrystal Pharma name after combining with Cocrystal Discovery in 2015. Cocrystal is headquartered in Bothell, Washington, and its research and development efforts are directed primarily toward potential antiviral treatments for markets in the United States and internationally.

View Cocrystal Pharma Profile
Earnings Tools